Avance Biosciences, a leading CRO that provides GLP/CGMP-compliant biological testing services that aid drug development and manufacturing, announced that it has signed a licensing agreement with SeQure Dx, a cutting-edge gene-editing diagnostics company. This agreement gives Avance access to SeQure Dx’s GUIDE-seq off-target next-generation sequencing (NGS) analysis methods, allowing Avance to support its clients’ CRISPR-based therapeutic programs by offering a comprehensive gene editing on/off-target analysis pipeline.
SeQure Dx’s GUIDE-seq is an NGS-based method that assesses the efficacy of genome editing tools such as CRISPR/Cas9. For many large pharma and biopharma companies, GUIDE-seq has become one of the most widely used methods to help characterize potential off-target events in their gene-editing therapeutics.
Also Read: Clovertex Achieves AWS Advanced Tier Services Partner Status
Avance provides comprehensive NGS services for both qualitative and quantitative analysis of gene editing profiles. Our CRISPR on/off-target analysis evaluates the potential off-target effects of single guide RNAs (sgRNAs), reducing the risk of unintended mutations. “We are excited to partner with SeQure Dx to provide our customers with access to this innovative NGS method,” said Xuening Huang, Ph.D., co-founder and CEO of Avance. “We believe that this agreement will enable us to further expand our portfolio of NGS services that aid in the biological drug development process, especially for cell-based therapies utilizing CRISPR technologies.”
SeQure Dx was founded on the ONE-seq technology discovered and developed by the Joung Lab at Massachusetts General Hospital and Harvard Medical School. SeQure Dx’s platform comprises the only scalable, population-based and editing technology-agnostic in vitro off-target evaluation method complemented by orthogonal methods required for off-target risk nomination as well as a portfolio of confirmation products to address the industry’s off-target unmet need.
SOURCE: PR Newswire